Chimeric Therapeutics Chimeric Therapeutics aspires to be a leader in cell therapy and to develop life-changing medicines for humankind We put patients first We demonstrate compassion and kindness to our patients and their families We strive to do the right thing Our people are our greatest assets We are intellectually curious Our science is data driven We are collaborative We value relationships based on trust and integrity We will be good stewards of our investors’ capital We will admit our mistakes and seek to learn from them We aim to have fun The value of our output must be worth more than the inputs
Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report 27/04/2022 11:53:00 Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31…
Chimeric Therapeutics - Strategic manufacturing partnership with WuXi ATU 12/04/2022 10:07:00 * Global contract testing and manufacturing organization WuXi Advanced Therapies (WuXi ATU) to support Chimeric CAR T cell programs * Enables Chimeric to accelerate manufacturing readiness for its …
Chimeric Therapeutics - Security Class Reinstatement to Quotation CHMO 28/03/2022 08:46:00 The suspension of trading in the options (ASX: CHMO) of Chimeric Therapeutics Limited (‘CHM’) will be lifted immediately. For more information, download the attached PDF.
Interviews / by Melissa Darmawan - 5 days ago Chimeric Therapeutics (ASX:CHM) expands cancer trials 18 May 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with…
Company Presentations / by - 2 months ago Chimeric Therapeutics (ASX:CHM) Presentation, FNN Investor Event, February 2022 25 Feb 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an overview of the company, discussing the company's cell therapy portfolio, …
Interviews / by Melissa Darmawan - 3 months ago Chimeric Therapeutics (ASX:CHM) - positive safety data for glioblastoma trial 08 Feb 2022 - Chimeric Therapeutics (ASX:CHM) CEO and Managing Director Jennifer Chow provides an overview progress since the company's IPO and discusses next steps.
Interviews / by Melissa Darmawan - 5 months ago Chimeric Therapeutics (ASX:CHM): Positive Initial Phase 1 Clinical Data 30 Nov 2021 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow talks about the recent presentation of data from the CHM 1101 (Chlorotoxin CAR T) Phas…
Company News / by Melissa Darmawan - 8 months ago Chimeric Therapeutics (ASX:CHM) appoints Jennifer Chow as CEO 30 Aug 2021 - Biotech innovator Chimeric Therapeutics (ASX:CHM) celebrates the appointment of Jennifer Chow as CEO.
Interviews / by Melissa Darmawan - 8 months ago Chimeric Therapeutics (ASX:CHM) - bringing cell therapy to more patients with cancer, August 2021 26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therap…
Interviews / by Melissa Darmawan - 11 months ago Chimeric Therapeutics (ASX:CHM) - clinical stage T cell therapy biotech targeting glioblastoma 07 Jun 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's phase 1 trial results for its chlorotoxin CAR T (CLTX CAR T) c…
Company Presentations / by - 11 months ago Chimeric Therapeutics (ASX:CHM) Presentation, FNN Online Investor Event, June 2021 03 Jun 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow presents on the company's chlorotoxin CAR T cell therapy for the treatment of glioblasto…
Market Reports / by Melissa Darmawan - A year ago ASX bounces back: Aus shares closes 0.8% higher 22 Apr 2021 - The ASX closed 0.8% higher to end the session shy of its 14-month high. Citi has downgraded Pilbara minerals (ASX:PLS) as a sell while Credit Suisse has downgraded Ch…
Company News / by Melissa Darmawan - A year ago Stocks of the Hour: OZ Minerals, Chimeric Therapeutics, AGL Energy 22 Apr 2021 - A snapshot of the top news for the hour featuring OZ Minerals, Chimeric Therapeutics, AGL Energy.
Company News / by Melissa Darmawan - A year ago Chimeric Therapeutics (ASX:CHM) reports successful 28-day follow up phase 1 trial 22 Apr 2021 - Biotech company Chimeric (ASX:CHM) reports the first cohort has moved successfuly beyond the 28-day follow up period.
Market Reports / by Anna Napoli - A year ago Retail results not enough to offset material losses: Aus shares close 0.8% lower 18 Jan 2021 - Australia’s sharemarket closed lower today despite a strong performance from some of our retailers. The S&P/ASX 200 index finished 52 points down or 0.8 per cent lowe…